Press Releases | January 19, 2017 |

OracleBio adds Visiopharm Oncotopix software for Image Analysis

OracleBio, a global leader in high precision, quantitative digital image analysis services, is pleased to announce an expansion of its software capabilities to include Visiopharm Oncotopix®. Produced by Denmark-based Visiopharm, Oncotopix® software is an advanced platform for computer assisted quantification of immunohistochemistry (IHC) and In-Situ Hybridization (ISH) staining. Oncotopix offers a portfolio of software modules designed for application within cancer diagnostics and for scientists within cancer research and drug development.

Lorcan Sherry, Chief Scientific Officer of OracleBio commented:

‘It is important that OracleBio continues to develop and deliver highly innovative histology image analysis services to support our Client’s pre-clinical and clinical R&D. Visiopharm Oncotopix is highly interactive and infinitely programmable, allowing OracleBio to custom configure image analysis requirements and define new algorithms to meet Clients’ specific requirements.’

Whilst Visiopharm offers a range of different solutions for digital pathology, the Oncotopix platform in particular will strengthen OracleBio’s Immuno-Oncology service offering. The software provides key features that support oncology research, such as virtual multiplexing, and is a powerful tool for advanced co-localisation studies and tumor detection.

Lars Pedersen, Director of Sales at Visiopharm, commented:

“Visiopharm is proud to include OracleBio in our growing base of pre-clinical and clinical CRO clients. The Oncotopix® solution that OracleBio has chosen is designed to match the increasing demand for high quality tissue-based biomarker analysis, shorter turn-around times and flexibility, and we are proud to fuel OracleBio in their ambitions to deliver innovative expert histopathology results with our proprietary solution for in vitro diagnostic applications.”

Along with OracleBio’s current analysis platform capabilities the addition of Visiopharm Oncotopix will further enhance the company’s service capabilities and puts OracleBio in the unique position of being a multi-image analysis platform service provider.

Share this article

Share the link on Twitter Share the link on LinkedIn

About OracleBio

OracleBio provides high quality precision Image Analysis histopathology quantification services to support Pharmaceutical R&D, Pathology review, biomarker research and tissue diagnostics development. As a highly specialised CRO OracleBio has extensive expertise in the development and application of custom image analysis algorithms to quantify drug response read-outs and biomarker expression in histologically stained pre-clinical and clinical tissue slides. OracleBio deliver highly detailed cell-by-cell data allowing for improved study interpretation and decision making within R&D. To find out more about OracleBio’s services, please contact us at


About Visiopharm

Visiopharm is a leading provider of quantitative image analysis software and end-to-end Digital Pathology solutions for Hospitals, biopharmaceutical companies and research institutions around the world. Recently, Visiopharm has expanded to include ONCOTOPIX® Diagnostics a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and VirtualDoubleStaining™. Visiopharm’s software is featured in over 1100 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and staining providers.

Visiopharm, a privately owned company, is an international business with over 750 licenses placed, with countless users, in more than 30 countries. A growing network of authorized distributors and integration partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia.

Learn everything about digital pathology

Latest news

Your message has been successfully sent!